Investigation of antiangiogenic tumor therapy potential of microencapsulated HEK293 VEGF165b producing cells

  1. (PDF, 634 KB)
  2. Get@NRC: Investigation of antiangiogenic tumor therapy potential of microencapsulated HEK293 VEGF165b producing cells (Opens in a new window)
DOIResolve DOI:
AuthorSearch for: ; Search for: ; Search for:
Journal titleJournal of Biomedicine and Biotechnology
Pages17; # of pages: 7
SubjectAcids; Adult; analysis; angiogenesis; Angiogenesis Inhibitors; Animal; animal experiment; animal tissue; antiangiogenic therapy; article; bio; Biotechnology; blood; Canada; cancer therapy; Cell Line; Cell Proliferation; cell strain HEK293; cell structure; cell viability; Cells; CHO cells; Cryopreservation; diagnosis; Endothelial Cells; endothelium cell; Fibroblasts; Gene Expression; Gene Therapy; Human; human cell; In Vitro; in vitro study; inhibitors; injuries; Kidney; Live; Liver; methods; Mice; microencapsulation; mouse; Mouse model; Neurons; nonhuman; NPArC; Nucleic Acids; peat; physiology; Protein; protein expression; protein production; rat; Recombinant protein; Recombinant protein production; Reproduction; surgery; synthesis; therapy; Transfection; umbilical vein; unclassified drug; vasculotropin 165; vasculotropin 165b; Vitro
AbstractTo investigate the antiangiogenic potential of encapsulated VEGF165b producing HEK293 cells, Human Embryonic Kidney 293 (HEK293) cells were stably transfected to produce VEGF165b. Then they were encapsulated in alginate - polylysine -alginate (APA) microcapsules. VEGF165b productivity and viability of encapsulated cells were analyzed and compared with the non-encapsulated cells. Results showed that encapsulated cells proliferated and remained viable within the microcapsules throughout the 28-day period of the experiment. The quantity of VEGF165b increased from 6.5 -� 1.2 g/ml at day 13 to 13 -� 0.96 g/ml at day 16. Then it gradually dropped to 5 -� 1.2 g/ml for the last 3 days period as measured at day 28. Production of VEGF165b from encapsulated and non-encapsulated cells was similar. The effect of VEGF165b harvested from encapsulated cells on Human Umbilical Vein Endothelial cells (HUVECs) proliferation were also examined.The same inhibitory effects on HUVECs proliferation was seen when the cells were incubated with a mixture of VEGF165b and a 2-fold VEGF165b or with VEGF165b and 2-fold excess VEGF165b released from encapsulated cells. Subcutaneous injection of microencapsulated VEGF165b producing cells in tumor site of nude mice resulted in the reduction of the number of vessels around the tumors. Copyright -� 2010 Fatemeh Afkhami et al
Publication date
AffiliationNRC Biotechnology Research Institute; National Research Council Canada
Peer reviewedYes
NRC number52776
NPARC number16616690
Export citationExport as RIS
Report a correctionReport a correction
Record identifier3ac7da47-0847-4089-abd1-a83e39f2e2f3
Record created2011-03-31
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)
Date modified: